Barrons.com • 19 days ago
Keryx Biopharmaceuticals (KERX:Nasdaq) By Maxim Group ($6.98, July 8, 2016) We spoke with Keryx Biopharmaceuticals management and left our conversation upbeat. The new Keryx (KERX) salesforce -- 95 reps and 11 regional managers, with the majority (two-thirds) being new -- is now in place and should be having an impact. This, combined with recent positive news flow (chronic kidney disease (CKD) trial), should begin to translate into quarterly revenue growth.
Capital Cube • 24 days ago
Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Keryx Biopharmaceuticals, Inc.Here are 5 ETF’s with the largest exposure to KERX-US. Comparing the performance and risk of Keryx Biopharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us […] (Read more...) The post ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : July 6, 2016 appeared first on CapitalCube.
CNBC • last month
Jim Cramer shares his opinion on various caller favorite stocks, including one stock with key data that could determine its future.
24/7 Wall St. • 2 months ago
A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as recent trading activity and the consensus price target.
Keryx Biopharmaceuticals Inc.NasdaqCM
After hours: 7.360.00 (0.02%) as of 4:48 PM EDT
|Bid||7.26 x 1000|
|Ask||7.56 x 1000|
|52wk Range||2.80 - 8.11|
|Day's Range||7.25 - 7.45|
|Avg Vol (3m)||1,300,090|
As of 4:00 PM EDT. Market closed.